Despite the well-established role of oncogenic RAS in promoting tumor formation, whether and how wild-type (WT) Ras inhibits tumorigenesis under physiological conditions remains controversial. Here, we show that in a fraction of endogenous oncogenic Kras-induced hematopoietic malignancies, including acute T-cell lymphoblastic leukemia/lymphoma (T-ALL) and myeloproliferative neoplasm (MPN), WT Kras expression is lost through epigenetic or genetic mechanisms. Using conditional Kras G12D/ − mice, we find that WT Kras deficiency promotes oncogenic Kras-induced MPN, but not T-ALL, in a cell-autonomous manner. Loss of WT Kras rescues oncogenic Kras-mediated hematopoietic stem cell depletion and further enhances granulocyte-macrophage colonystimulating factor signaling in myeloid cells expressing oncogenic Kras. Quantitative signaling studies reveal that oncogenic Kras but not oncogenic Nras leads to cross-activation of WT Ras, whereas loss of WT Kras further promotes the activation of all Ras isoforms. Our results demonstrate the tumor suppressor function of WT Kras in oncogenic Kras-induced leukemogenesis and elucidate its underlying cellular and signaling mechanisms.
INTRODUCTION
Ras proteins belong to small GTPase superfamily. They cycle between the active GTP-bound form and the inactive GDP-bound form. Conversion between these states occurs through intrinsic nucleotide exchange (from GDP-bound form to GTP-bound form) or GTP hydrolysis (from GTP-bound form to GDP-bound form). Numerous proteins facilitate these conversions, including Ras-GEFs (guanine nucleotide exchange factors that promote the release of GDP and the association of GTP) and Ras-GAPs (GTPase-activating proteins that accelerate GTP hydrolysis by Ras proteins). 1, 2 In human cancers, hyperactivation of Ras signaling is achieved mainly through two mechanisms. 3 First, Ras proteins are hyperactivated by the constitutive activation of a protein tyrosine kinase upstream of Ras (for example, constitutively active FLT3 and Bcr-Abl) or inactivation of a Ras-GAP (for example, NF-1). Second, acquired oncogenic RAS mutations disrupt Ras GTPase activities (for example, mutations on Q61 codon) or their association with Ras-GAPs (for example, mutations on G12 and G13 codons). In both cases, Ras proteins are accumulated in an active GTP-bound form and promote tumorigenesis. 4 Compelling evidence demonstrates that oncogenic Ras proteins have dominant gain-of-function actions in tumorigenesis. Earlier in vivo and in vitro studies suggested that this dominance might result from either overexpression of the mutant RAS allele or deletion of the wild-type (WT) allele. 5, 6 Subsequent observations that WT Ras allele is deleted in tumor cells carrying its corresponding oncogenic allele raise an interesting hypothesis that loss of the WT Ras allele facilitates tumorigenesis mediated by the oncogenic Ras allele. 7, 8 Although genetic studies in mice support the idea that WT Ras acts as a tumor suppressor in some solid cancers, 9 ,10 the underlying mechanisms are largely unknown. Interestingly, a recent study reports that loss of WT Nras does not promote leukemogenesis driven by an endogenous oncogenic Nras.
11 This is contradictory to an earlier report demonstrating that WT Nras suppresses thymic lymphomagenesis in the presence of oncogenic Nras when oncogenic Nras is overexpressed in Nras −/− mice or in mice overexpressing WT Nras.
12 Therefore, it remains controversial whether the tumor suppressor function of WT Ras in vivo is restricted to specific Ras isoforms and/or to solid tumor types under physiological conditions.
Here, we show that in a fraction of oncogenic Kras-induced hematopoietic malignancies, including acute T-cell lymphoblastic leulemia/lymphoma (T-ALL) and myeloproliferative neoplasm (MPN), WT Kras expression is lost. To determine whether and how loss of WT Kras expression promotes oncogenic Krasinduced leukemogenesis, we generated conditional Kras G12D/ − mice. We find that WT Kras deficiency promotes oncogenic Krasinduced MPN in a cell-autonomous manner. Two mechanisms significantly contributed to this leukemogenic activity. First, loss of WT Kras rescues oncogenic Kras-mediated depletion of hematopoietic stem cells (HSCs), which serve as MPN-initiating cells. Second, loss of WT Kras further hyperactivates granulocytemacrophage colony-stimulating factor (GM-CSF) signaling in myeloid progenitor (MP) and precursor cells expressing oncogenic Kras, driving their proliferation in vivo and growth in vitro. Quantitative Ras-GTP assay reveals that oncogenic Kras but not oncogenic Nras leads to cross-activation of WT Ras. Loss of WT Kras further promotes activation of all Ras isoforms. Our results demonstrate the tumor suppressor function of WT Kras in oncogenic Kras-induced MPN and elucidate its underlying mechanisms.
MATERIALS AND METHODS Mice
All mouse lines were maintained in a pure C57BL/6 genetic background (4N10 ; Mx1-Cre mice were generated as previously described or described above.
13-15 CD45.1-positive congenic C57BL/6-recipient mice were purchased from NCI (National Cancer Institute 16 Four weeks after transplantation, Cre expression was induced through intraperitoneal injection of 5 μg/g body weight of polyinosinic-polycytidylic acid (GE Healthcare, Chicago, IL, USA) once. Fluorescence-activated cell sorting analysis of peripheral blood was performed at 4-week intervals after transplantation.
Immunoprecipitation and western blot analysis
To detect the level of Ras-GTP, affinity purification of Ras-GTP from 20 × 10 6 bone marrow cells was performed as previously described. 17 Primary antibodies used for western blotting against Nras, Kras and β-actin were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Primary antibody against Hras was purchased from Abcam (ab32417, Cambridge, UK). The chemiluminescent signals were detected using ImageQuant LAS4000 (GE Healthcare). Quantification of western blot results was performed using ImageJ software.
Statistics
Kaplan-Meier survival analysis was performed and survival differences between groups were assessed with the Log-rank test, assuming significance at Po0.05. Unpaired two-tailed Student's t-tests were used . to determine the significance between two data sets, assuming significance at P o0.05.
Additional methods are described in Supplementary Materials and Methods.
RESULTS

A fraction of oncogenic Kras-induced T-ALL and MPN lose WT Kras expression
In oncogenic Kras-induced T-ALL, we previously found a high variability in the frequency of T-cell leukemia-initiating cells that did not consistently correlate with the mutational status of Notch1.
18 Therefore, we hypothesized that other genetic mutations might contribute to T-ALL progression. Given the long-standing observation that WT Ras serves as a tumor suppressor in oncogenic Ras-induced solid tumors in mouse, 9 ,10,12 we first investigated WT Kras status in three mouse T-ALL cell lines derived from oncogenic Kras mice. 16 Indeed, WT Kras mRNA expression was undetectable in all three cell lines ( Figure 1a ). WT Kras locus remained intact in two of the cell lines, but was lost in the third one, suggesting that silencing WT Kras expression could be mediated by both epigenetic and genetic mechanisms.
To determine when loss of WT Kras expression occurred in vivo, we examined five pre-T-ALL and 12 frank T-ALL samples 18 ( Figure 1b) . We found that expression of WT Kras was readily detectable in all five pre-T-ALL samples, whereas 3 of 12 T-ALL samples showed loss of WT Kras expression at both the mRNA and genomic DNA levels. These data suggested that loss of WT Kras might promote T-ALL progression, but not T-ALL initiation. To distinguish whether loss of WT Kras was due to uniparental disomy of oncogenic Kras allele or deletion of WT Kras allele, we performed a customized high-density CGH analysis around the Kras locus on mouse chromosome 6 ( Figure 1c ). In all three T-ALL samples that lost WT Kras expression, the WT Kras allele was deleted.
We further investigated whether loss of WT Kras expression also occurred during oncogenic Kras-induced MPN. We genotyped the bone marrow cells isolated from seven primary Kras G12D/+ mice (6-week old) with an early stage of MPN and four moribund recipients that were transplanted with Kras G12D/+ cells and developed a severe MPN (Figure 1d ). One out of seven primary ; Mx1-Cre mice were born at the expected Mendelian ratio, they were overtly smaller, presumably due to the leaky expression of Cre. In 6-week-old mice without polyinosinic-polycytidylic acid injection,~67% of Kras LSL G12D/+ HSCs expressed the oncogene and~55% of Kras LSL G12D/fl ; Mx1-Cre HSCs expressed oncogenic Kras and deleted WT Kras (Supplementary Figure S1c) . As expected, Kras G12D/+ and Kras G12D/ − cells were predominant in bone marrow and spleen in these mice, respectively (Supplementary Figure S1d) . Therefore, we took the advantage of leaky expression of Mx1-Cre and did not perform polyinosinicpolycytidylic acid injection in these animals. We refer to Kras Figure S2a) . However, the MPN phenotypes in Kras G12D/ − mice were significantly more severe than those in Kras G12D/+ mice, as demonstrated by increased splenomegaly (Figure 2b ), leukocytosis and more severe thrombocytopenia in the peripheral blood (Figure 2c) , and expanded myeloid compartments in various hematopoietic tissues (Figure 2d) (Figure 3 ). Four weeks after transplantation, we injected polyinosinic-polycytidylic acid once to achieve a better recombination efficiency at the Kras locus in the recipients. Because the HSC frequency in Kras G12D/+ spleen was comparable to that in Kras G12D/ − spleen (Figure 5a ), recipients transplanted with Kras G12D/+ or Kras G12D/ − splenocytes showed similar contribution of donor-derived cells in the peripheral blood, bone marrow and spleen of recipient mice (Figures 3a and b) . All the recipients transplanted with Kras G12D/+ cells died in 15 weeks posttransplantation, whereas recipients with Kras G12D/ − cells survived significantly shorter (Figure 3c ). Approximately 75% of recipients with Kras G12D/+ cells died with significantly enlarged thymi (indicative of T-ALL), whereas~42% of them developed MPN with anemia, monocytosis and thrombocytopenia, and splenomegaly ( Figure 4 and Supplementary Figure S2b) . In contrast,~91% of recipients with Kras G12D/ − cells developed Figure 5 . Loss of wild-type Kras rescues Kras G12D -mediated HSC depletion. Control (C), Kras G12D/+ (G/+) and Kras G12D/ − (G/ − ) mice were killed 6 weeks after birth for analysis of hematopoietic stem cells (HSCs) (a), multipotential progenitor cells (MPPs) (b), and Lin − Sca-1 + c-Kit + cells (LSKs) (c), in hind limb bone marrow (BM (HL)) and spleen (SP). The absolute HSC, MPP and LSK numbers in BM (HL) and SP were calculated based on bone marrow or spleen cell numbers and frequencies. Because BM (HL) represents 25% of whole body bone marrow, 26 the total number of stem/progenitor cells per animal was calculated as the sum of stem/progenitor cell number in spleen and fourfold of stem/ progenitor cell number in BM (HL). The results are presented as mean ± s.d. *P o0.05, **P o0.01; ***P o0.001. a lethal MPN, with MPN phenotypes that were significantly more severe than those in recipients with Kras G12D/+ cells ( Figure 4 and Supplementary Figure S2b) . Although only~36% of mice with Kras G12D/ − cells died with T-ALL, all these tumor samples carried Notch1 type 1 deletions as has been described in Kras G12D/+ -induced T-ALL 18 (Supplementary Figure S3) . Our data suggest that loss of WT Kras indeed promotes oncogenic Kras-induced MPN in a cell-autonomous manner.
Loss of WT Kras rescues oncogenic Kras-mediated HSC depletion We investigated how loss of WT Kras promotes oncogenic Krasinduced MPN. Because mutant HSCs serve as MPN-initiating cells in these animals, 16, 19 we first examined the HSC compartment in 6-week-old animals ( Figure 5) (Figure 5c ). ERK1/2 signaling in Kras G12D/ − HSCs and MPPs was comparable to that in Kras G12D/+ cells, but significantly hyperactivated than control cells (Figure 6a) . Consistent with our prior publication, 21 Akt was not hyperactivated in mutant HSCs, but was moderately hyperactivated in mutant MPPs isolated from spleen (Supplementary Figure S4) . HSCs, MPPs and LSKs in Kras G12D/ − mice were much more proliferative than those in Kras G12D/+ mice (Figures 6b and c) . Together, these data suggest that loss of WT Kras appears to induce proliferation in HSCs expressing oncogenic Kras and rescue their depletion. Owing to the rapid on-set of leukemogenesis in these recipients (Figure 3c ), we could not evaluate the long-term self-renewal capability of Kras G12D/+ and Kras G12D/ − HSCs in a serial transplantation assay.
Loss of WT Kras promotes colony-forming capability of oncogenic Kras-expressing MPs by further enhancing GM-CSF signaling Because the manifestation of MPN phenotypes is driven by rapidly growing MPs, we investigated the MP compartment in 6-week-old The results are presented as mean ± s.d. *P o0.05, **P o0.01; ***P o0.001. mice ( Figure 7 and Supplementary Figure S5) . Consistent with previous reports, 20, 22 the MP compartment in Kras G12D/+ bone marrow was significantly reduced compared with that in control as both common myeloid progenitor and megakaryocyteerythrocyte progenitor compartments were reduced (Figure 7a and Supplementary Figure S5) . In contrast, the MP compartment in Kras G12D/+ spleen was significantly expanded due to increased numbers of common myeloid progenitors, granulocyte-monocyte progenitor and megakaryocyte-erythrocyte progenitor. Therefore, the overall MP number in Kras G12D/+ mice was comparable to that in control mice. However, loss of WT Kras resulted in significant increase of overall MP number due to the further expansion of MP compartment in spleen. Consistent with our flow cytometric analysis, splenocyte colony-forming assays indicated that Kras G12D/+ cells formed much larger and more numerous colonies than control cells under the same culture conditions, whereas Kras G12D/ − cells displayed more marked phenotypes than Kras G12D/+ cells (Figure 7b and Supplementary Figure S6) . Cell cycle analysis showed that Kras G12D/ − MPs were significantly hyperpoliferative than control MPs (Figure 7c ). Our results demonstrated that loss of WT Kras promotes the proliferation/growth of oncogenic Kras-expressing MPs, which also contributes to the more severe MPN phenotypes in Kras G12D/ − mice. We investigated whether GM-CSF signaling was further hyperactivated in Kras G12D/ − MPs as compared with Kras Figure S7) . Moreover, loss of WT Kras led to a further increase in Kras G12D -GTP, Nras-GTP and Hras-GTP levels. Consequently, the level of total Ras-GTP in Kras G12D/ − cells was significantly higher than that in Kras G12D/+ cells. Notably, the elevated Ras-GTP levels did not associate with elevated Ras protein levels. Quantification of individual Ras isoforms and total Ras against β-actin showed that their expression levels were comparable among control, Kras G12D/+ and Kras G12D/ − cells.
DISCUSSION
In this study, we show that loss of WT Kras expression occurs in a significant fraction of oncogenic Kras-induced T-ALL and MPN. Moreover, in vivo loss of WT Kras promotes oncogenic Kras-induced MPN in a cell-autonomous manner. This enhanced leukemogenic activity mediated by WT Kras deficiency is attributed to HSC rescue and increased proliferation/growth of MPs. Detailed signaling studies reveal that loss of WT Kras leads to increased activation of all Ras isoforms and consequently further hyperactivation of cytokine signaling in cells expressing oncogenic Kras.
We found that all three T-ALL cell lines derived from oncogenic Kras mice and~25% of oncogenic Kras-induced Figure 7 . Loss of wild-type Kras increases colony-forming capability of Kras G12D myeloid progenitor cells. Control (C), Kras G12D/+ (G/+) and Kras G12D/ − (G/ − ) mice were killed 6 weeks after birth for analysis of myeloid progenitor (MP) cells. (a) Quantitative analysis of MPs in bone marrow (BM) and spleen (SP). The absolute MP numbers in BM (HL) and SP were calculated based on bone marrow or spleen cell numbers and frequencies. Because BM (HL) represents 25% of whole body bone marrow, 26 the total number of stem/progenitor cells per animal was calculated as the sum of stem/progenitor cell number in spleen and fourfold of stem/progenitor cell number in BM (HL). (b) Splenocytes were cultured in methylcellulose-based medium M3234 supplemented with various concentrations of purified mGM-CSF or mIL-3 as described in Materials and methods. The colonies were counted after 7 days in culture. (c) Cell cycle analysis of MP cells using Ki67 and DAPI. The results are presented as mean ± s.d. *P o0.05, **P o0.01 and ***P o0.001.
T-ALL specimens lost WT Kras expression through distinct mechanisms (Figures 1a-c) . In T-ALL cell lines, loss of WT Kras expression was mediated by either epigenetic silencing or a genetic mechanism, whereas in primary T-ALL samples, loss of WT Kras expression was due to deletion of WT Kras locus. Our results are consistent with a human study of early T-cell precursor ALL, which identified KRAS G12D/ − mutations in patient tumor cells. 23 However, our result is contradictory to a prior study reporting that loss of WT Kras expression in oncogenic Kras-induced T-ALL is due to uniparental disomy of oncogenic Kras Figure 8 . Loss of wild-type Kras hyperactivates ERK1/2 and further increases RAS-GTP levels in Kras G12D cells. Control (C), Kras G12D/+ (G/+) and Kras G12D/ − (G/ − ) mice were killed 6 weeks after birth for analysis. (a) Whole bone marrow cells were serum-and cytokine-starved for 2 h at 37°C. Cells were then stimulated with different concentrations of mGM-CSF for 10 min at 37°C. Levels of p-ERK1/2 and p-STAT5 were measured using phospho-flow cytometry. Non-neutrophil bone marrow cells were gated for data analysis. Myeloid progenitors are enriched in Lin − /low c-Kit + cells, whereas myeloid precursors are enriched in Lin − /low c-Kit − cells. Data are presented as mean ± s.d. (b) Whole cell lysates (WCL) were extracted from total bone marrow cells and assayed for expression levels of different Ras isoforms. Ras-GTP was affinity purified from WCL using a GST fusion with the Ras-binding domain of Raf (Raf RBD) immobilized on agarose beads. Different Ras isoforms and total Ras bound with GTP were analyzed using western blot analyses. The results were quantified using ImageJ software. Levels of total Ras and individual Ras isoforms in WCL were quantified against the level of β-actin. The ratios of Ras-GTP/Ras in Kras G12D/+ cells are arbitrarily set at 1. Data are presented as mean+s.d. *Po 0.05, **Po 0.01; ***Po 0.001.
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